The stories you’ve read the most in 2023 (so far)

From staff shortages to presidential candidates and the M&A outlook, here are our most-read stories from the first half of the year.

By PharmaVoice Staff • July 3, 2023

A pharma summer — how leaders unwind and recharge their teams in the warmer months

Vacation is calling, but so are patients. Here's how the industry adjusts in the summer. 

By Michael Gibney • June 30, 2023

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Major clinical trial trends transforming life sciences research

From AI to diversity and decentralized trials, here’s how clinical trial operations are evolving.

By Karissa Waddick • June 29, 2023

Transgender patients are rarely included in clinical trials. Can pharma fix it?

Transgender and nonbinary patients suffer more adverse health outcomes than the general population, yet are often underrepresented in clinical research. Now, there’s momentum to change the status quo.

By Karissa Waddick • June 29, 2023

Pharma is still figuring out how to make DEI work. Here are some of the strategies companies are trying

Although DEI efforts have ramped up, the industry is still searching for proven ways to get results.

By Alexandra Pecci • June 28, 2023

Intercept’s NASH retreat is the latest setback for a challenging liver disease

Intercept Pharmaceuticals has stepped out of the race to the first U.S. approved treatment for the complicated liver disease NASH, leaving room for other pharmas to get their foot in the door.

By Michael Gibney • June 27, 2023

A unique study on COVID shows how machine learning can help personalize medicine

Based on real-world data from patients in China, researchers were able to pinpoint factors that led to recurring infections — and which drug combos helped.

By Kelly Bilodeau • June 26, 2023

How Sanofi is taking a ‘creative’ approach to dealmaking

Dr. Monika Vnuk, SVP of global partnering and business development, is setting her sights on out-of-the-box partnerships.

By Taren Grom • June 23, 2023

10 years proud: Pharma’s top companies for LGBTQ+ inclusivity

These six Big Pharma companies have ranked among the best places to work for LGTBQ+ equality by the Human Rights Campaign Foundation for over 10 years. Here’s why. 

By Karissa Waddick , Taren Grom • June 22, 2023

Duty to serve: an Army officer’s unexpected path to GSK

How Court Horncastle, SVP, business unit head of the anti-infective and respiratory team at GSK, applies lessons from combat to his work in antibiotics.

By Alexandra Pecci • June 21, 2023

The spotlight is on accelerated approvals — now FDA could run a tighter ship

As the fallout of the Aduhelm approval continues, scrutiny of the speedier pathway has increased and the pressure is on to close a key gap in the regulation.

By Kelly Bilodeau • June 20, 2023

AI has secured a footing in drug discovery. Where does it go from here?

The AI revolution is bringing a new era of drug discovery, and the potential for more uses is greater and faster than ever before.

By Michael Gibney • June 20, 2023

Shaking up pharma: Change that leaders would like to see

Industry execs give voice to the “game changers” they believe would have the greatest impact on the healthcare ecosystem for all.

By Taren Grom • June 16, 2023

How pharma execs are approaching drug pricing and other quandaries

From implementation of the Inflation Reduction Act, to the looming patent cliff and more, pharma leaders have a lot on their plates.

By Karissa Waddick • June 16, 2023

Boosting the cell and gene therapy workforce with a skilled, localized approach

Experts provide a roadmap for how the industry can work with academia to ensure a robust talent pipeline for the burgeoning field.

By Karissa Waddick • June 15, 2023

How steep is pharma’s patent cliff?

The big pharma patent cliff is almost here — and could change the face of the industry. Here’s a look at the key stats behind the coming wave of blockbuster losses.  

By Meagan Parrish • June 14, 2023

The ingredients of a successful biopharma collaboration

Collaboration is important along the entire spectrum and lifecycle of biopharma, and finding an effective partner is harder than it sounds.

By Michael Gibney • June 13, 2023

Is America ready for a new kind of opioid?

Tris Pharma’s CEO is “betting the company” on a pain reliever with the power of an opioid and a lower chance of addiction. 

By Alexandra Pecci • June 12, 2023

Why cancer could be the ideal realm for psychedelic treatments

The CEO of Sunstone Therapies said the results of a recent trial testing psilocybin in cancer patients with depression were “remarkable.”

By Meagan Parrish • June 9, 2023

Yes, biopharma still has a reputation problem. These leaders are looking for solutions.

Negative news is breaking down the public’s perception of the biopharma industry — but leaders around the industry have some ideas to fix it.

By Michael Gibney • June 8, 2023

FDA’s decentralized trials guidance leaves slate of fresh questions for industry

Recent FDA guidance aims to bolster DCT adoption but provides little clarity on the patchwork of telemedicine laws that pose an obstacle to the approach.

By Karissa Waddick • June 8, 2023

Woman of the Week: Marinus Pharmaceuticals’ Christy Shafer

The chief commercial officer shares how the company “beat the odds” to bring a rare disease drug to market.

By Taren Grom • June 7, 2023

Ranking reveals biopharma’s most innovative companies

IDEA Pharma’s 12th index finds that Pfizer and AstraZeneca reign supreme again.

By Taren Grom • June 7, 2023

Janssen and Legend’s longtime collaboration lands a CAR-T win at ASCO

A partnership going on six years between the pharma giant and the Chinese biotech is showing that their CAR-T cell therapy for multiple myeloma is highly effective.

By Michael Gibney • June 5, 2023

Drugmakers feel the squeeze as cost pressures mount

Supply chain challenges have eased — but now inflation and manufacturing complexity are triggering a new sense of urgency to bring costs down.

By Kelly Bilodeau • June 5, 2023